Developing intrabodies for the therapeutic suppression of neurodegenerative pathology

Expert Opinion on Biological Therapy

Volumn 9, Issue 9, 2009, Pages 1189-1197

  Messer, Anne ^a,b   Lynch, Sandra M ^a,b   Butler, David C ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Alzheimer's; Amyloid; Antibody therapeutics; Huntington's; Intrabody; Neurodegeneration; Parkinson's; Prion; scFv

Indexed keywords

ALPHA SYNUCLEIN; CELL ANTIBODY; HEAT SHOCK PROTEIN 70; HUNTINGTIN; INTRACELLULAR ANTIBODY; INTRACELLULAR ANTIBODY C4; INTRACELLULAR ANTIBODY HAPP1; INTRACELLULAR ANTIBODY HAPP3; INTRACELLULAR ANTIBODY MW1; INTRACELLULAR ANTIBODY MW2; INTRACELLULAR ANTIBODY MW7; LEUCINE RICH REPEAT KINASE 2; MONOCLONAL ANTIBODY EM48; PARVOVIRUS VECTOR; POLYGLUTAMINE; PROLINE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DRUG POTENTIATION; DRUG PROTEIN BINDING; GENETIC ENGINEERING; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

ANIMALS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; NEURODEGENERATIVE DISEASES;

EID: 68949159773     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903176387     Document Type: Review

References (99)

1. Carlson JR. A new means of inducibly inactivating a cellular protein. Mol Cell Biol 1988;8(6):2638-2646
2. Mukhtar MM, Li S, Li W, et al. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int J Biochem Cell Biol 2009;41(3):554-560
3. Aires da Silva F, Santa-Marta M, Freitas-Vieira A, et al. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol 2004;340(3):525-542 (Pubitemid 38797998)
4. Doorbar J, Griffin H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther 2007;7(5):677-689 (Pubitemid 46707190)
5. Marasco WA, Chen S, Richardson JH, et al. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther 1998;9(11):1627-1642 (Pubitemid 28382964)
6. Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008;(181):343-373
7. Tanaka T, Williams RL, Rabbitts TH. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007;26(13):3250-3259 (Pubitemid 47057484)
8. Groot AJ, Gort EH, van der Wall E, et al. Conditional inactivation of HIF-1 using intrabodies. Cell Oncol 2008;30(5):397-409
9. Messer A, McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on huntington and Parkinson diseases. Biodrugs 2006;20(6):327-333 (Pubitemid 46089658)
10. Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 2005;12(3):394-401 (Pubitemid 41158094)
11. Cardinale A, Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med 2008;14(9):373-380
12. Zhou C, Przedborski S. Intrabody and Parkinson's disease. Biochim Biophys Acta 2009;1792(7):634-642
13. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86(10):3833-3837 (Pubitemid 19141839)
14. Holt LJ, Herring C, Jespers LS, et al. Domain antibodies: proteins for therapy. Trends Biotechnol 2003;21(11):484-490
15. Paz K, Brennan LA, Iacolina M, et al. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 2005;4(11):1801-1809 (Pubitemid 41685315)
16. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods 2004;290(1-2):69-80
17. Lecerf JM, Shirley TL, Zhu Q, et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001;98(8):4764-4769 (Pubitemid 32295050)
18. Colby DW, Chu Y, Cassady JP, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 2004;101(51):17616-17621 (Pubitemid 40051935)
19. Emadi S, Liu R, Yuan B, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004;43:2871-2878 (Pubitemid 38327818)
20. Visintin M, Tse E, Axelson H, et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA 1999;96(21):11723-11728 (Pubitemid 29502799)
21. Visintin M, Settanni G, Maritan A, et al. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 2002;317(1):73-83 (Pubitemid 34722200)
22. Philibert P, Stoessel A, Wang W, et al. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 2007;7:81. Published online 22 November 2007, doi:10.1186/1472-6750-7-81 (Pubitemid 351250512)
23. Muyldermans S, Baral TN, Retamozzo VC, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 2009;128(1-3):178-183
24. Habicht G, Haupt C, Friedrich RP, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci USA 2007;104(49):19232- 19237
25. Chartier A, Raz V, Sterrenburg E, et al. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet 2009;18(10):1849-1859
26. Shuntao W, Jiannan F, Jianwei G, et al. A novel designed single domain antibody on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity. Mol Immunol 2006;43(11):1912-1919
27. Davies J, Riechmann L. 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett 1994;339(3):285-290
28. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72(6):971-983
29. Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995;269(5222):407-410
30. Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009;19(4):147-155
31. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008;412(2):191-209 (Pubitemid 351758226)
32. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 2009;1792(6):506-520
33. Sapp E, Schwarz C, Chase K, et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997;42(4):604-612 (Pubitemid 27439023)
34. Difiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277(5334):1990-1993 (Pubitemid 27449140)
35. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998;4(6):387-397
36. Becher MW, Ross CA. Intranuclear neuronal inclusions in DRPLA. Mov Disord 1998;13(5):852-853
37. Skinner PJ, Koshy BT, Cummings CJ, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997;389(6654):971-974
38. Holmberg M, Duyckaerts C, Durr A, et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 1998;7(5):913-918 (Pubitemid 28221256)
39. Paulson HL, Das SS, Crino PB, et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 1997;41(4):453-462 (Pubitemid 27169184)
40. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999;19(7):2522-2534 (Pubitemid 29162401)
41. Atwal RS, Xia J, Pinchev D, et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007;16(21):2600-2615 (Pubitemid 47617727)
42. Cornett J, Cao F, Wang CE, et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005;37(2):198-204
43. Omi K, Hachiya NS, Tanaka M, et al. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Neurosci Lett 2008;431(1):45-50
44. Rockabrand E, Slepko N, Pantalone A, et al. The first 17 amino acids of huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007;16(1):61-77 (Pubitemid 46156597)
45. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004;5(10):958-963
46. Hatters DM. Protein misfolding inside cells: the case of huntingtin and Huntington's disease. IUBMB Life 2008;60(11):724-728
47. Kvam E, Nannenga BL, Wang MS, et al. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One 2009;4(5):e5727. Published online: 28 May, 2009, doi:10.1371/journal.pone.0005727
48. Lecerf J-M, Shirley TL, Zhu Q, et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. PNAS 2001;98(8):4764-4769 (Pubitemid 32295050)
49. Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res Mol Brain Res 2004;121:141-145 (Pubitemid 38224179)
50. Miller TW, Zhou C, Gines S, et al. A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease. Neurobiol Dis 2005;19:47-56 (Pubitemid 40552820)
51. Auerbach W, Hurlbert MS, Hilditch-Maguire P, et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 2001;10(22):2515-2523 (Pubitemid 33095002)
52. Southwell AL, Khoshnan A, Dunn DE, et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 2008;28(36):9013-9020
53. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA 2002;99(2):1002-1007 (Pubitemid 34106625)
54. Ko J, Ou S, Patterson PH. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 2001;56(3-4):319-329 (Pubitemid 33062356)
55. Baker JD, McNabb SL, Truman JW. The hormonal coordination of behavior and physiology at adult ecdysis in Drosophila melanogaster. J Exp Biol 1999;202(Pt 21):3037-3048
56. Wolfgang WJ, Miller TW, Webster JM, et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005;102:11563-11568
57. McLear JA, Lebrecht D, Messer A, Wolfgang WJ. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J 2008;22:2003-2011 (Pubitemid 351811476)
58. Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998;21(3):633-642 (Pubitemid 28475514)
59. Wang CE, Zhou H, McGuire JR, et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 2008;181(5):803-816 (Pubitemid 351786985)
60. Lewis PA. Emerging pathways in genetic Parkinson's disease. FEBS J 2008;275(23):5747
61. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-840
62. Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 1998;3(6):493-499 (Pubitemid 28515524)
63. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 2008;64(Suppl 2):S56-64
64. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51(2 Suppl 2):S2-9
65. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003;42(26):7871-7878
66. Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9(10):1231-1233 (Pubitemid 44454261)
67. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001;276(4):2380-2386 (Pubitemid 37376605)
68. Singleton AB, Farrer M, Johnson J, et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841 (Pubitemid 37339619)
69. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-2047 (Pubitemid 27443610)
70. Li W, West N, Colla E, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 2005;102(6):2162-2167 (Pubitemid 40262029)
71. Periquet M, Fulga T, Myllykangas L, et al. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007;27(12):3338-3346 (Pubitemid 46474139)
72. Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 2008;377(1):136-147
73. Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel 2006;19(11):497-502 (Pubitemid 44627322)
74. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004;10(6):1023-1031 (Pubitemid 39625246)
75. Wang MS, Zameer A, Emadi S, Sierks MR. Characterizing antibody specificity to different protein morphologies by AFM. Langmuir 2009;25(2):912-918
76. Emadi S, Barkhordarian H, Wang MS, et al. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007;368(4):1132-1144 (Pubitemid 46574670)
77. Emadi S, Kasturirangan S, Wang MS, et al. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem 2009;284(17):11048- 11058
78. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009;1(1), published online 14 April 2009 published online 14 April 2009 doi: 10.1042/AN20090007
79. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-607 (Pubitemid 39531225)
80. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102(46):16842-16847 (Pubitemid 41688864)
81. Gloeckner CJ, Kinkl N, Schumacher A, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006;15(2):223-232 (Pubitemid 43125977)
82. Li X, Tan YC, Poulose S, et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007;103(1):238-247 (Pubitemid 47404210)
83. West AB, Moore DJ, Choi C, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16(2):223-232 (Pubitemid 46179004)
84. Devine MJ, Lewis PA. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J 2008;275(23):5748-5757
85. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62(9):1619-1622 (Pubitemid 38608210)
86. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353- 356 (Pubitemid 34790756)
87. Paganetti P, Calanca V, Galli C, et al. Beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol 2005;168(6):863-868 (Pubitemid 40397001)
88. Paganetti PA, Lis M, Klafki HW, Staufenbiel M. Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. J Neurosci Res 1996;46(3):283-293 (Pubitemid 26376362)
89. Zameer A, Kasturirangan S, Emadi S, et al. Anti-oligomeric Aβ single-chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells. J Mol Biol 2008;384(4):917-928
90. Meli G, Visintin M, Cannistraci I, Cattaneo A. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J Mol Biol 2009;387(3):584-606
91. Fukuchi K, Tahara K, Kim HD, et al. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006;23(3):502-511 (Pubitemid 44234087)
92. Levites Y, Jansen K, Smithson LA, et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 2006;26(46):11923-11928 (Pubitemid 44772103)
93. Wang YJ, Pollard A, Zhong JH, et al. Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease. Neurobiol Aging 2009;30(3):364-376
94. Campana V, Zentilin L, Mirabile I, et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2009;418(3):507-515
95. Donofrio G, Heppner FL, Polymenidou M, et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79(13):8330-8338 (Pubitemid 40853536)
96. Vetrugno V, Cardinale A, Filesi I, et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem Biophys Res Commun 2005;338(4):1791-1797 (Pubitemid 41643092)
97. Zuber C, Mitteregger G, Schuhmann N, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008;89(Pt 8):2055-2061
98. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008;16(3):481-486 (Pubitemid 351314986)
99. Filesi I, Cardinale A, Mattei S, Biocca S. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrPSc formation. J Neurochem 2007;101(6):1516-1526 (Pubitemid 46848843)